SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about company updates

23 Nov 2024 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a Collaboration and License Agreement on November 22, 2024 with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation. Additional disclosures as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in Annexure.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1479.20 15.60 (1.07%)
05-Jun-2026 10:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1792.40
Dr. Reddys Lab 1275.00
Cipla 1389.00
Zydus Lifesciences 1090.00
Lupin 2273.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×